Zydus Cadila receives final approval from USFDA for Deferasirox Tablets

Zydus Cadila has received final approval from the USFDA to market Deferasirox Tablets (US RLD: Jadenu™ Tablets) in the strengths of 90 mg, 180 mg and 360 mg.

Deferasirox binds to iron and removes it from the bloodstream. It is used to treat iron overload caused by blood transfusions in adults and children who are at least 2 years old. It is also used to treat chronic iron overload syndrome caused by a genetic blood disorder (non-transfusion dependent thalassemia) in adults and children who are at least 10 years old.

The drug will be manufactured at the group’s manufacturing facility at SEZ, Anmedabad.

The group now has 291 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.370.7 as compared to the previous close of Rs. 374. The total number of shares traded during the day was 196726 in over 5857 trades.

The stock hit an intraday high of Rs. 383.65 and intraday low of 369.2. The net turnover during the day was Rs. 73995653.

Source : Equity Bulls

Keywords